Drug reaction with eosinophilia and systemic symptoms syndrome (DRESS) syndrome associated with azithromycin presenting like septic shock: a case report
Journal of Medical Case Reports volume 8, Article number: 332 (2014)
Drug reaction with eosinophilia and systemic symptoms syndrome is a potentially life-threatening cutaneous hypersensitivity reaction characterized by extensive mucocutaneous eruption, fever, hematologic abnormalities including eosinophilia and/or atypical lymphocytosis, and extensive organ involvement. The drugs most often responsible for causing drug reaction with eosinophilia and systemic symptoms syndrome are anticonvulsants, antimicrobial agents and antipyretic or anti-inflammatory analgesics. Although azithromycin is widely prescribed in clinical practice, serious cutaneous reactions from this agent have been rarely described. We report the first adult case of drug reaction with eosinophilia and systemic symptoms syndrome associated with azithromycin.
A 44-year-old previously healthy Caucasian man with history of tobacco use presented to his primary care physician with fever and productive cough. He was prescribed azithromycin, promethazine hydrochloride and dextromethorphan hydrobromide syrup. One week later, he developed a blistering erythematous rash over both hands, which over the next two weeks spread to involve nearly his entire body surface, sparing only his face. He was admitted to an outside hospital with signs of systemic inflammatory response syndrome and severe sepsis, presumably from a skin infection. Despite aggressive therapy he deteriorated, with worsening diffuse erythema, and was transferred to our institution. He developed multiple organ failure requiring ventilatory and hemodynamic support. Pertinent laboratory studies included a leukocytosis with a white blood cell count of 17.6×109/L and 47% eosinophils. A skin biopsy showed evidence of spongiotic lichenoid dermatitis with eosinophils and neutrophils, compatible with a systemic drug-induced hypersensitivity reaction. Our patient was started on high-dose steroids and showed dramatic improvement within 48 hours.
We report the first adult case of drug reaction with eosinophilia and systemic symptoms syndrome associated with azithromycin exposure. Clinicians should be aware of this potentially devastating complication from this commonly prescribed medication.
Cutaneous hypersensitivity reactions range in severity, from mild reactions to severe cutaneous adverse reactions, or SCARs. SCARs include a spectrum of disease from erythema multiforme (EM) to drug reaction with eosinophilia and systemic symptoms (DRESS) to toxic epidermal necrolysis (TEN), the most serious form of drug reaction. Mild adverse cutaneous reactions to drugs are common, occurring in up to 2% to 3% of all hospitalized patients . Of all the cutaneous adverse reaction, 2% of cases are severe and very few are fatal .
DRESS syndrome is a potentially life-threatening reaction characterized by extensive mucocutaneous eruption, fever, hematologic abnormalities including eosinophilia and/or atypical lymphocytosis, and extensive internal organ involvement . Long-term sequelae and multiple organ involvement include myocarditis or pericarditis, interstitial nephritis, necrotizing granulomatous vasculitis, encephalitis or meningitis, as well as shock and respiratory distress syndrome. The drugs most often responsible are anticonvulsants (mostly aromatase derivatives), antimicrobial agents, particularly penicillin and sulfonamide-based agents, and antipyretic/anti-inflammatory analgesics [2, 4]. DRESS syndrome has a latency onset, characteristically occurring within two to six weeks after initial exposure to the inciting drug. In a few reported cases, the syndrome becomes persistent despite discontinuation of the culprit drug .
Azithromycin is widely prescribed for acute respiratory tract infection. The majority of adverse events from azithromycin are mild to moderate in severity and related to the gastrointestinal tract. Drug rash is observed in approximately 6% of cases . However, severe cutaneous reactions have been rarely reported and none have developed DRESS syndrome according to our literature search. Here we report the potential first case of DRESS syndrome associated with azithromycin.
A 44-year-old otherwise healthy Caucasian man, with a past medical history of anxiety and 15 pack year tobacco use, initially presented to his primary care physician with several days onset of fevers, congestion and cough. He was prescribed azithromycin, promethazine hydrochloride and dextromethorphan hydrobromide syrup. One week later, the patient developed an acute diffuse blistering morbilliform erythematous rash involving bilateral hands, which was extremely pruritic and associated with high-grade fever. Within two weeks, the rash spread to involve nearly his entire body surface, sparing only his face. He presented to an outside hospital with persistent fever, rash, and hypotension consistent with systemic inflammatory response syndrome. He was treated for severe sepsis and presumptive superimposed skin infection with vancomycin and aztreonem, given his history of penicillin allergy. Despite aggressive therapy, the patient rapidly deteriorated with worsening skin involvement, and was subsequently transferred to our institution for higher level care.Upon arrival, his vital signs were temperature of 38.2°C, blood pressure of 95/20mmHg, heart rate 68 beats/min, respiratory rate 20 breaths/min, and oxygen saturation 95% on 2L nasal canula. Shortly thereafter, our patient became hypotensive despite aggressive fluid resuscitation and was started on norepinephrine. Our patient was subsequently intubated due to worsening level of consciousness. A physical examination revealed an ill-appearing sedated man with evidence of generalized ill-defined coalescing erythema and diffuse pinpoint petechiae. A pulmonary examination was notable for bilateral crackles and diffuse rhonchi and a cardiovascular examination was normal except for tachycardia. There was no lymphadenopathy. A detailed skin examination (Figure 1) revealed keratotic desquamation of his palms and soles. His lips and oral mucosa were dry with some cracking of vermilion lips but no bullae. His tongue was diffusely red. His conjunctivae were injected. There were no vesicles, bullae, or target lesions seen. The Nikolsky sign was negative.
Laboratory studies revealed leukocytosis with a white blood cell count of 17.6×109/L with 47% eosinophils, 33% neutrophils, 5% bands, and 12% lymphocytes as well as thrombocytopenia of 117×109/L. No atypical lymphocytes were seen on the peripheral blood smear or manual differential. His blood chemistry test results were notable for blood urea nitrogen of 21.4mmol/L, serum creatinine 229μmol/L, albumin 21g/L, alkaline phosphatase 188μg/L, aspartate aminotransaminase 58IU/mL, and alanine aminotransferase 37IU/mL. Serological test results including HIV titer, leptospira antibody, and streptolysin O antibody were all nonreactive. His blood cultures, urine culture, herpes simplex wound culture, as well as varicella zoster wound cultures were all unremarkable. Coccidioides serology was negative. His chest X-ray was consistent with pulmonary edema (Figure 2). Results from a diagnostic bronchoscopy showed evidence of diffuse mucosal hyperemia from the trachea through the subsegmental bronchi but no sloughing. Bronchial washing studies including bacterial, viral and fungal cultures, as well as pneumocystis jiroveci DFA, were all unremarkable.
Despite an exhaustive workup noted above and consultation with dermatology, infectious disease, ophthalmology, pulmonary and burn specialists, no clear etiology was identified. Over the next several days, he continued to worsen despite broad-spectrum antibiotics including vancomycin, meropenem and clindamycin. He developed low-grade disseminated intravascular coagulation (DIC), worsening leukocytosis, worsening renal failure as well as persistent hypotension requiring high levels of norepinephrine.On hospital day 4, results from his skin biopsy showed evidence of spongiotic lichenoid dermatitis with eosinophils and neutrophils (Figures 3 and 4), compatible with systemic drug hypersensitivity reaction. No evidence of vasculitis was seen on histopathology. Our patient was started on high-dose steroids and all antibiotics were discontinued, given no convincing evidence of infection. He was weaned off norepinephrine and extubated shortly thereafter. His fever resolved and his generalized body rash dramatically improved over the course of 48 hours with supportive treatment (Figure 5). Our patient subsequently made a full recovery after an additional week of rehabilitation and was discharged home.
DRESS syndrome is a severe drug reaction with a mortality rate up to 10% despite accurate diagnosis and removal of the offending agent. Diagnosis is challenging and often delayed, given its variable presentation. Currently, there are no accurate diagnostic criteria for DRESS but it is a syndrome diagnosed by exclusion. The main clinical features are rash, fever, hematological abnormalities and organ involvement, all of which can be nonspecific. The RegiSCAR scoring system has been recently developed to delineate each of severe cutaneous adverse reactions (SCARs) as distinct entities . The RegiSCAR scoring system was designed to grade suspected cases of DRESS as ‘no’ , ‘possible’ , ‘probable’ or ‘definite’. DRESS is considered as definite in our case given that other causes of febrile eruption with eosinophilia and liver involvement were ruled out. We suspect that azithromycin is likely the culprit medication in this scenario. Promethazine may also produce drug reactions, but the association with DRESS syndrome has not been reported. There are two available methods of confirming the culprit drug of DRESS syndrome: skin patch tests and lymphocyte transformation tests . Unfortunately, neither is widely accepted or used.
According to one recent review of 172 DRESS cases, there are 44 drugs associated with DRESS . Of these, the most frequently reported were carbamazepine, allopurinol, sulfasalazine, phenobarbital, lamotrigine and nevirapine. Azithromycin has not been shown to cause DRESS in adults. Thus far, there have been only two reported pediatric cases of DRESS associated with azithromycin [10, 11]. One of the cases was also associated with Epstein-Barr virus (EBV) primary infection. Pursnani et al. reported a case of fulminant myocarditis in an adult associated with azithromycin , which was presumed to be DRESS syndrome; however, the RegiSCAR scoring system was not reported.
The pathophysiology of DRESS syndrome has not been fully elucidated. Different mechanisms have been implicated, including detoxification defects leading to reactive metabolite formation and subsequent immunological reactions, slow acetylation, and reactivation of human herpes, including EBV and human herpesvirus (HHV)-6 and -7 . The association of HHV-6 infection or reactivation and severe DRESS syndrome has also been reported . It is postulated that HHV-6 may interfere with some of the enzymes responsible for drug detoxification. The virus itself could also be responsible for the skin lesions and some of the visceral involvement . The recent studies suggest that HHV-6 reactivation activates CD8+ T lymphocytes causing it to secrete cytokines .
There are no consensus guidelines on the management of DRESS syndrome. The mainstay of treatment is discontinuing the culprit drug. The use of systemic steroids is controversial including the route of administration and dosing .
In summary, we report the first adult case of definite DRESS syndrome associated with azithromycin exposure. Early recognition and prompt removal of the culprit agent is the treatment of choice.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
disseminated intravascular coagulation
drug reaction with eosinophilia and systemic symptoms
severe cutaneous adverse reactions
toxic epidermal necrolysis.
Bigby M, Jick S, Jick H, Arndt K: Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA. 1986, 256: 3358-3363. 10.1001/jama.1986.03380240052027.
Alanko K, Stubb S, Kauppinen K: Cutaneous drug reactions: clinical types and causative agents. A five-year survey of in-patients (1981-1985). Acta Derm Venereol. 1989, 69: 223-226.
Walsh SA, Creamer D: Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking. Clin Exp Dermatol. 2011, 36: 6-11. 10.1111/j.1365-2230.2010.03967.x.
Wang F, Li Y, Mo Y, Shen C, Yang L, Zhang X: Cutaneous adverse drug reactions: an 8-year retrospective study on hospitalized patients in Southern China. Indian J Dermatol Venereol Leprol. 2012, 78: 488-490. 10.4103/0378-6323.98082.
Bocquet H, Bagot M, Roujeau JC: Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg. 1996, 15: 250-257. 10.1016/S1085-5629(96)80038-1.
Harris JA, Kolokathis A, Campbell M, Cassell GH, Hammerschlag MR: Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children. Pediatr Infect Dis J. 1998, 17: 865-871. 10.1097/00006454-199810000-00004.
Kardaun SH, Sidoroff A, Valeyrie-Allanore L, Halevy S, Davidovici BB, Mockenhaupt M, Roujeau JC: Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?. Br J Dermatol. 2007, 156: 609-611. 10.1111/j.1365-2133.2006.07704.x.
Husain Z, Reddy BY, Schwartz RA: DRESS syndrome: part II. Management and therapeutics. J Am Acad Dermatol. 2013, 68: 709-e1-9; quiz 718-720
Cacoub P, Musette P, Descamps V, Meyer O, Speirs C, Finzi L, Roujeau JC: The DRESS syndrome: a literature review. Am J Med. 2011, 124: 588-597. 10.1016/j.amjmed.2011.01.017.
Bauer KA, Brimhall AK, Chang TT: Drug reaction with eosinophilia and systemic symptoms (DRESS) associated with azithromycin in acute Epstein-Barr virus infection. Pediatr Dermatol. 2011, 28: 741-743. 10.1111/j.1525-1470.2011.01558.x.
Schmutz JL, Trechot P: [DRESS associated with azithromycin in a child]. Ann Dermatol Venereol. 2013, 140: 75-10.1016/j.annder.2012.09.006.
Pursnani A, Yee H, Slater W, Sarswat N: Hypersensitivity myocarditis associated with azithromycin exposure. Ann Intern Med. 2009, 150: 225-226. 10.7326/0003-4819-150-3-200902030-00027.
Ichiche M, Kiesch N, DeBels D: DRESS syndrome associated with HHV-6 reactivation. Eur J Intern Med. 2003, 14: 498-500. 10.1016/j.ejim.2003.09.004.
Picard D, Janela B, Descamps V, D’Incan M, Courville P, Jacquot S, Rogez S, Mardivirin L, Moins-Teisserenc H, Toubert A, Benichou J, Joly P, Musette P: Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response. Sci Transl Med. 2010, 2: 46ra62-
We would like to thank Dr. Maxwell A. Fung, who provided us with the pathology pictures.
The authors declare that they have no competing interests.
NS, LN, MH and TA collected patient data and administered therapy. NS wrote the manuscript. LN, MH and TA revised and edited the manuscript. All authors read and approved the final manuscript.
About this article
Cite this article
Sriratanaviriyakul, N., Nguyen, LP., Henderson, M.C. et al. Drug reaction with eosinophilia and systemic symptoms syndrome (DRESS) syndrome associated with azithromycin presenting like septic shock: a case report. J Med Case Reports 8, 332 (2014). https://doi.org/10.1186/1752-1947-8-332
- DRESS syndrome
- Drug allergy
- Drug-induced hypersensitivity syndrome
- Azithromycin hypersensitivity